Illumina (NASDAQ:ILMN – Get Rating) had its price target cut by stock analysts at Canaccord Genuity Group from $555.00 to $520.00 in a report released on Friday, The Fly reports. The brokerage presently has a “buy” rating on the life sciences company’s stock. Canaccord Genuity Group’s price target suggests a potential upside of 104.97% from the company’s current price.
A number of other equities analysts also recently weighed in on the stock. Robert W. Baird lowered their target price on shares of Illumina from $437.00 to $380.00 in a research note on Friday, February 11th. Cowen dropped their price target on Illumina from $506.00 to $492.00 in a research note on Friday. OTR Global raised shares of Illumina from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 29th. Piper Sandler boosted their price target on shares of Illumina from $450.00 to $460.00 and gave the company an “overweight” rating in a research report on Tuesday, February 15th. Finally, Stifel Nicolaus upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $480.00 price target for the company in a research report on Tuesday, January 18th. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $440.77.
ILMN traded down $38.03 during trading hours on Friday, reaching $253.69. The company’s stock had a trading volume of 39,281 shares, compared to its average volume of 726,629. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.09 and a current ratio of 2.48. The company’s 50-day moving average is $332.29 and its 200-day moving average is $359.37. Illumina has a 52 week low of $287.73 and a 52 week high of $526.00. The firm has a market cap of $39.85 billion, a PE ratio of 50.11, a price-to-earnings-growth ratio of 2.33 and a beta of 0.99.
In other Illumina news, SVP Phillip G. Febbo sold 1,988 shares of the business’s stock in a transaction on Wednesday, April 6th. The stock was sold at an average price of $360.01, for a total transaction of $715,699.88. Following the sale, the senior vice president now directly owns 5,774 shares in the company, valued at $2,078,697.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Aimee L. Hoyt sold 2,474 shares of the firm’s stock in a transaction on Tuesday, April 12th. The stock was sold at an average price of $350.51, for a total value of $867,161.74. Following the transaction, the senior vice president now directly owns 5,342 shares of the company’s stock, valued at approximately $1,872,424.42. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,198 shares of company stock worth $1,819,471. Corporate insiders own 0.13% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. Biondo Investment Advisors LLC raised its stake in Illumina by 5.2% during the third quarter. Biondo Investment Advisors LLC now owns 40,861 shares of the life sciences company’s stock worth $16,574,000 after purchasing an additional 2,003 shares during the period. Cambridge Investment Research Advisors Inc. grew its stake in Illumina by 39.5% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 10,628 shares of the life sciences company’s stock worth $4,043,000 after buying an additional 3,009 shares during the period. CHICAGO TRUST Co NA increased its position in shares of Illumina by 7.1% in the fourth quarter. CHICAGO TRUST Co NA now owns 1,890 shares of the life sciences company’s stock worth $719,000 after acquiring an additional 125 shares in the last quarter. NS Partners Ltd boosted its position in Illumina by 0.8% during the 3rd quarter. NS Partners Ltd now owns 39,759 shares of the life sciences company’s stock worth $16,127,000 after purchasing an additional 302 shares during the period. Finally, Capital Fund Management S.A. acquired a new stake in Illumina in the 3rd quarter valued at $20,974,000. Institutional investors own 86.62% of the company’s stock.
Illumina Company Profile (Get Rating)
Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
- Get a free copy of the StockNews.com research report on Illumina (ILMN)
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
- Peak Growth Is Over For Etsy
- Kellogg Company Flexes Pricing Power, Shares Move Higher
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.